Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.

Abstract

Translation is regulated predominantly at the initiation phase by several signal transduction pathways that are often usurped in human cancers, including the PI3K/Akt/mTOR axis. mTOR exerts unique administration over translation by regulating assembly of eukaryotic initiation factor (eIF) 4F, a heterotrimeric complex responsible for recruiting 40S ribosomes (and associated factors) to mRNA 5' cap structures. Hence, there is much interest in targeted therapies that block eIF4F activity to assess the consequences on tumor cell growth and chemotherapy response. We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Eμ-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness. As Mcl-1 levels are significantly affected by Hipp, combining its use with the Bcl-2 family inhibitor, ABT-737, leads to a potent synergistic response in triggering cell death in mouse and human lymphoma and leukemia cells. Suppression of eIF4AI using RNA interference also synergized with ABT-737 in murine lymphomas, highlighting eIF4AI as a therapeutic target for modulating tumor cell response to chemotherapy.

• Authors: R Cencic, F Robert, G Galicia-Vázquez, A Malina, K Ravindar, R Somaiah, P Pierre, J Tanaka, P Deslongchamps, J Pelletier
• Journal: Blood cancer journal (Blood Cancer J) Vol. 3 Pg. e128 (Jul 19 2013) ISSN: 2044-5385 [Print] United States
• PMID: 23872707 (Publication Type: Journal Article)